Semaglutide Acetate 是胰高血糖素样肽 1 (GLP-1) 受体的激动剂，可用于治疗 2 型糖尿病的研究。

Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.

Semaglutide Acetate is a long-acting GLP-1 analogue with GLP-1 receptor affinity of 0.38 nM[3].

Semaglutide Acetate improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. Semaglutide Acetate rescues the decrease of tyrosine hydroxylase (TH) levels, reduces lipid peroxidation, inhibits the apoptosis pathway, alleviates the inflammation response, increases autophagy-related protein expression, and protects dopaminergic neurons in the substantia nigra and striatum[2]. In mini-pigs, The plasma half-life of Semaglutide Acetate (i.v.) is 46h and the MRT of Semaglutide Acetate (s.c.) is 63.6h[3].

T19850L

#N/A

#N/A

索玛鲁肽醋酸盐;Semaglutide Acetate(910463-68-2 Free base)

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years